PT2194121T - Método de proliferação celular e agente farmacêutico para reparação e regeneração de tecidos - Google Patents

Método de proliferação celular e agente farmacêutico para reparação e regeneração de tecidos

Info

Publication number
PT2194121T
PT2194121T PT88309893T PT08830989T PT2194121T PT 2194121 T PT2194121 T PT 2194121T PT 88309893 T PT88309893 T PT 88309893T PT 08830989 T PT08830989 T PT 08830989T PT 2194121 T PT2194121 T PT 2194121T
Authority
PT
Portugal
Prior art keywords
repairing
pharmaceutical agent
cellular proliferation
regenerating tissues
regenerating
Prior art date
Application number
PT88309893T
Other languages
English (en)
Inventor
Honmou Osamu
Houkin Kiyohiro
Original Assignee
Univ Sapporo Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2007235436A external-priority patent/JP2009065854A/ja
Priority claimed from JP2007236499A external-priority patent/JP2009065884A/ja
Priority claimed from JP2007278083A external-priority patent/JP2009100719A/ja
Priority claimed from JP2007278049A external-priority patent/JP2009107929A/ja
Application filed by Univ Sapporo Medical filed Critical Univ Sapporo Medical
Publication of PT2194121T publication Critical patent/PT2194121T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
PT88309893T 2007-09-11 2008-09-10 Método de proliferação celular e agente farmacêutico para reparação e regeneração de tecidos PT2194121T (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2007235436A JP2009065854A (ja) 2007-09-11 2007-09-11 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2007236499A JP2009065884A (ja) 2007-09-12 2007-09-12 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2007267211 2007-10-12
JP2007278083A JP2009100719A (ja) 2007-10-25 2007-10-25 改善された増殖能を有する細胞およびその評価方法
JP2007278049A JP2009107929A (ja) 2007-10-12 2007-10-25 損傷部位の修復を幇助する非経口全身投与剤

Publications (1)

Publication Number Publication Date
PT2194121T true PT2194121T (pt) 2016-12-05

Family

ID=42113874

Family Applications (2)

Application Number Title Priority Date Filing Date
PT161829809T PT3117828T (pt) 2007-09-11 2008-09-10 Método de proliferação celular, e agente farmacêutico para reparação e regeneração de tecidos
PT88309893T PT2194121T (pt) 2007-09-11 2008-09-10 Método de proliferação celular e agente farmacêutico para reparação e regeneração de tecidos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT161829809T PT3117828T (pt) 2007-09-11 2008-09-10 Método de proliferação celular, e agente farmacêutico para reparação e regeneração de tecidos

Country Status (12)

Country Link
US (3) US9700582B2 (pt)
EP (2) EP2194121B1 (pt)
JP (1) JP4936341B2 (pt)
KR (3) KR20160005140A (pt)
CN (1) CN101802174B (pt)
AU (1) AU2008298816B2 (pt)
CA (1) CA2699236C (pt)
DK (2) DK2194121T3 (pt)
ES (2) ES2611021T3 (pt)
PL (2) PL2194121T3 (pt)
PT (2) PT3117828T (pt)
WO (1) WO2009034708A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008298816B2 (en) * 2007-09-11 2013-09-26 Sapporo Medical University Cell growth method and pharmaceutical preparation for tissue repair and regeneration
DK2602310T3 (da) * 2010-08-03 2020-02-24 Univ Sapporo Medical Autoserum-indeholdende knoglemarvcelledyrkningssystem, autoserum-indeholdende knoglemarvcelledyrkningsfremgangsmåde, og fremgangsmåde til fremstilling af en lægemiddelsammensætning omfattende (...)
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
CN107267449B (zh) 2013-02-06 2021-03-19 Nc医学研究公司 用于治疗神经变性的细胞疗法
EP3041929B1 (en) * 2013-09-05 2019-03-13 The Regents of The University of California Adipose-derived mesenchymal stem cells for oral stomatitis treatment
US12171786B2 (en) 2015-10-05 2024-12-24 The Regents Of The University Of California Use of mesenchymal stem cells for the treatment of inflammation
CN105566460B (zh) * 2016-01-19 2018-11-23 南通大学 抑制肿瘤细胞增殖的多肽类似物和对应的编码cDNA及应用
JP6781973B2 (ja) * 2016-01-29 2020-11-11 学校法人東京女子医科大学 腎臓病進行抑制細胞シート組成物、その製造方法、及び、それを用いた腎臓病進行抑制方法
CN109069542A (zh) 2016-04-28 2018-12-21 北海道公立大学法人札幌医科大学 突触形成剂
CN106153919B (zh) * 2016-06-16 2018-06-29 汕头大学医学院 CD105，esVEGR2和MYC三蛋白联合预测食管鳞癌患者预后试剂盒
JP7076709B2 (ja) * 2016-08-18 2022-05-30 北海道公立大学法人 札幌医科大学 間葉系幹細胞活性化剤
US20190183937A1 (en) * 2016-08-18 2019-06-20 Sapporo Medical University Life extension agent
JP7089283B2 (ja) 2016-08-30 2022-06-22 国立大学法人 新潟大学 細胞製剤および細胞製剤の製造方法
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
JP6438527B2 (ja) * 2017-06-01 2018-12-12 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法
CN109517789B (zh) * 2017-09-19 2022-05-27 北京大学 Ghrelin活性剂用于诱导干细胞向软骨细胞分化
CN111343997A (zh) 2017-11-09 2020-06-26 北海道公立大学法人札幌医科大学 组织再生用药物和其制造方法
CN110174512B (zh) * 2018-04-04 2022-06-03 首都医科大学附属北京地坛医院 sCD163检测试剂在梅毒检测中的应用及包括该试剂的试剂盒
JP7353652B2 (ja) * 2018-04-25 2023-10-02 北海道公立大学法人 札幌医科大学 生体移植用細胞シート及びその製造方法
CN110870917B (zh) * 2018-09-03 2022-03-15 上海市第一人民医院 Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用
US20220125850A1 (en) * 2019-02-07 2022-04-28 Sapporo Medical University Pharmaceutical composition for preventing in-stent restenosis
JP7541699B2 (ja) * 2019-03-14 2024-08-29 北海道公立大学法人 札幌医科大学 筋萎縮性側索硬化症の治療用医薬組成物
WO2020256628A1 (en) 2019-06-20 2020-12-24 Amniotics Ab An apparatus for filtering amniotic fluid
JP7714535B2 (ja) 2019-10-18 2025-07-29 アムニオティクス・アーベー 羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置
CN112899223A (zh) * 2019-12-04 2021-06-04 陕西光子动力航天科技有限公司 宫血干细胞制备方法
JP7663202B2 (ja) * 2019-12-27 2025-04-16 北海道公立大学法人 札幌医科大学 哺乳動物細胞を培養するための血清の製造方法
JP7328729B2 (ja) 2020-03-31 2023-08-17 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 細胞の保存方法
JP7444267B2 (ja) * 2020-09-03 2024-03-06 株式会社ツーセル 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
CN112826920A (zh) * 2021-01-23 2021-05-25 中国人民解放军陆军军医大学 Id1/id3在诱导成纤维细胞重编程为施万细胞促进神经再生的应用
CN113652491A (zh) * 2021-02-02 2021-11-16 暨南大学 m6A RNA甲基化含量及其甲基化相关酶和结合蛋白在制备衰老检测试剂盒中的应用
US20230075134A1 (en) * 2021-08-31 2023-03-09 Joshua Medical Holdings Co. Ltd. Method for isolating and purifying mesenchymal stem cells from hernia sac and method for tissue repair by using mesenchymal stem cells from hernia sac
CN114164216B (zh) * 2021-12-21 2023-08-25 北京航空航天大学 一种基因在促进骨形成中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038139A (en) * 1976-07-16 1977-07-26 G. D. Searle & Co., Limited Cell culture medium
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
JP3211941B2 (ja) 1996-12-26 2001-09-25 科学技術振興事業団 ヒト小型肝細胞の取得方法と、この細胞の初代培養および継代培養方法
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
WO2001048147A1 (en) 1999-12-28 2001-07-05 Iso Tis N.V. Cell culture medium containing growth factors and l-glutamine
EP2295539A1 (en) * 2000-06-26 2011-03-16 Nc Medical Research Inc. Cell fractions containing cells capable of differentiating into neural cells
JP2003052360A (ja) 2001-08-20 2003-02-25 Japan Science & Technology Corp 基底膜細胞外基質を用いた間葉系幹細胞の培養方法
US20040259254A1 (en) 2001-10-30 2004-12-23 Osamu Honmou Method for inducing differentiation mesodermal stem cells, es cells or immortalized cells into nervous system cells
JP2003235548A (ja) 2001-12-13 2003-08-26 Japan Science & Technology Corp ヒト細胞の培養用培地および培養方法
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
CA2517108A1 (en) * 2003-02-25 2004-09-10 Tokai University Medium for stem cells in regeneration of intervertebral disc and regeneration of intervertebral disc using stem cells
KR101130220B1 (ko) 2003-06-27 2012-04-13 엔씨 메디컬 리서치 가부시키가이샤 간엽계 세포를 유효 성분으로 하는 뇌신경 질환 치료용 체내 투여용 약제
WO2005001732A1 (ja) 2003-06-27 2005-01-06 Renomedix Institute Inc. 治療用自己細胞配送支援システム及び治療用自己細胞配送支援金融システム、並びにそれらの方法
US20060210544A1 (en) * 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
US20070178591A1 (en) * 2004-06-25 2007-08-02 Renomedix Institute, Inc Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient
CN1590537A (zh) * 2003-09-02 2005-03-09 中国人民解放军第四军医大学口腔医学院 外胚间充质干细胞的分离和培养方法
JP4651282B2 (ja) 2004-01-21 2011-03-16 田辺三菱製薬株式会社 造血幹細胞及び造血前駆細胞の増幅方法
JP4597538B2 (ja) 2004-02-03 2010-12-15 独立行政法人産業技術総合研究所 神経幹細胞増殖助剤及びこれを含んだ神経幹細胞用培地
JP2006034118A (ja) * 2004-07-23 2006-02-09 Kaneka Corp 間葉系幹細胞の効率的保存または調製方法
JP2006055106A (ja) 2004-08-23 2006-03-02 National Institute Of Advanced Industrial & Technology ヒト血清培地を用いるヒト骨髄由来間葉系幹細胞培養法
JP2006136281A (ja) * 2004-11-15 2006-06-01 Olympus Corp 培地および間葉系幹細胞の培養方法
WO2006054448A1 (ja) * 2004-11-19 2006-05-26 Jms Co., Ltd. 細胞培養用ヒト血清
CN1699557A (zh) * 2005-05-26 2005-11-23 南开大学 一种骨髓间充质干细胞的分离及培养方法
US20070047270A1 (en) 2005-09-01 2007-03-01 Creative Technology Ltd. Load detector for an AC-AC power supply
US20080199849A1 (en) 2005-09-02 2008-08-21 Agency For Science, Technology And Research Method of Deriving Progenitor Cell Line
JP2007235436A (ja) 2006-02-28 2007-09-13 Sunx Ltd 電子回路及び光電センサ
JP5170967B2 (ja) 2006-03-06 2013-03-27 株式会社大一商会 遊技機
JP4719604B2 (ja) 2006-03-29 2011-07-06 エヌ・ティ・ティ アイティ株式会社 コマーシャル検出方法およびコマーシャル検出装置並びにコマーシャル検出プログラムが記録された記録媒体
JP4779775B2 (ja) 2006-04-03 2011-09-28 日産自動車株式会社 内燃機関の吸気制御装置
JP2007278049A (ja) 2006-04-07 2007-10-25 Voice Interface:Kk 凝固剤注入によるアスベスト封じ込めシステム
AU2008298816B2 (en) * 2007-09-11 2013-09-26 Sapporo Medical University Cell growth method and pharmaceutical preparation for tissue repair and regeneration

Also Published As

Publication number Publication date
EP3117828A1 (en) 2017-01-18
KR102087366B1 (ko) 2020-03-10
US11426432B2 (en) 2022-08-30
PT3117828T (pt) 2020-03-17
US10328102B2 (en) 2019-06-25
EP2194121A1 (en) 2010-06-09
KR101614823B1 (ko) 2016-04-22
CA2699236A1 (en) 2009-03-19
US20190255118A1 (en) 2019-08-22
EP3117828B1 (en) 2020-02-12
KR20160005140A (ko) 2016-01-13
EP2194121B1 (en) 2016-10-26
WO2009034708A1 (ja) 2009-03-19
US20100254953A1 (en) 2010-10-07
KR20170116219A (ko) 2017-10-18
CN101802174B (zh) 2013-06-05
JPWO2009034708A1 (ja) 2010-12-24
AU2008298816B2 (en) 2013-09-26
CN101802174A (zh) 2010-08-11
PL3117828T3 (pl) 2020-05-18
AU2008298816A1 (en) 2009-03-19
CA2699236C (en) 2017-02-28
JP4936341B2 (ja) 2012-05-23
PL2194121T3 (pl) 2017-02-28
US9700582B2 (en) 2017-07-11
US20170266234A1 (en) 2017-09-21
KR20100072240A (ko) 2010-06-30
ES2611021T3 (es) 2017-05-04
ES2776408T3 (es) 2020-07-30
EP2194121A4 (en) 2012-03-07
DK2194121T3 (en) 2016-12-12
DK3117828T3 (da) 2020-03-09

Similar Documents

Publication Publication Date Title
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
PT3117828T (pt) Método de proliferação celular, e agente farmacêutico para reparação e regeneração de tecidos
BRPI0807918A2 (pt) composições e método para preservação de tecido
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BRPI0821080A2 (pt) Composições de gel de polissacarídeo e métodos para liberação sustentada de fármacos
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0719912A2 (pt) Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
BRPI0819755A2 (pt) composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0817290A2 (pt) Métodos, dispositivos, sistemas, conjuntos, e kits para retração de tecido dentro de uma cavidade oral
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0807958A2 (pt) Método e equipamento para handover inter-sistemas
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0815416A2 (pt) Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
BRPI0714959A2 (pt) Composição de peneira molecular, método para fabricação e processo para uso do mesmo
BR112013019083A2 (pt) combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0806994A2 (pt) Método e equipamento para tradução de endereço
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI0815881A2 (pt) Composição de revestimento de poliuretano e método para tratar uma surpeficie envelhecida
BRPI0910963A2 (pt) composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BRPI0923534A2 (pt) composição e método para tratamento de doenças de pele